Halper Sadeh Investigates AtaiBeckley’s $6.75 Per Share Sale to Eli Lilly
Event summary
- Halper Sadeh LLC is investigating AtaiBeckley’s sale to Eli Lilly for $6.75 per share in cash plus up to $2.50 per share in Contingent Value Rights.
- The law firm questions whether AtaiBeckley’s board obtained the best price, conducted a fair process, and disclosed all material information.
- The investigation focuses on potential violations of federal securities laws and breaches of fiduciary duties.
- Halper Sadeh may seek increased consideration or other relief for shareholders.
The big picture
This investigation underscores growing scrutiny over biopharma M&A, particularly in deals involving contingent value rights. Shareholder activism is rising as investors demand greater transparency in valuation and process. The outcome could set a precedent for future transactions in the sector.
What we're watching
- Governance Dynamics
- Whether AtaiBeckley’s board can justify the valuation and process under scrutiny.
- Regulatory Headwinds
- How potential legal challenges could impact the deal’s timeline or terms.
- Execution Risk
- The pace at which Eli Lilly integrates AtaiBeckley’s pipeline and whether milestones are met.
Related topics